Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia.
AML
CSC
HSC
LSC
acute myeloid leukemia
cancer stem cells
cellular differentiation
computational biology
computational method
hematopoietic stem cells
leukemic stem cells
single-cell RNA-seq
single-cell genomics
single-cell transcriptomics
Journal
Cell stem cell
ISSN: 1875-9777
Titre abrégé: Cell Stem Cell
Pays: United States
ID NLM: 101311472
Informations de publication
Date de publication:
04 05 2023
04 05 2023
Historique:
received:
29
07
2022
revised:
05
02
2023
accepted:
30
03
2023
medline:
8
5
2023
pubmed:
26
4
2023
entrez:
25
4
2023
Statut:
ppublish
Résumé
Inter-patient variability and the similarity of healthy and leukemic stem cells (LSCs) have impeded the characterization of LSCs in acute myeloid leukemia (AML) and their differentiation landscape. Here, we introduce CloneTracer, a novel method that adds clonal resolution to single-cell RNA-seq datasets. Applied to samples from 19 AML patients, CloneTracer revealed routes of leukemic differentiation. Although residual healthy and preleukemic cells dominated the dormant stem cell compartment, active LSCs resembled their healthy counterpart and retained erythroid capacity. By contrast, downstream myeloid progenitors constituted a highly aberrant, disease-defining compartment: their gene expression and differentiation state affected both the chemotherapy response and leukemia's ability to differentiate into transcriptomically normal monocytes. Finally, we demonstrated the potential of CloneTracer to identify surface markers misregulated specifically in leukemic cells. Taken together, CloneTracer reveals a differentiation landscape that mimics its healthy counterpart and may determine biology and therapy response in AML.
Identifiants
pubmed: 37098346
pii: S1934-5909(23)00119-4
doi: 10.1016/j.stem.2023.04.001
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
706-721.e8Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The Department of Medicine V (Director C.M.-T.) receives research funding from multiple pharmaceutical and biotech companies especially for clinical trials but also for translational research.